drugset / Trial / NCT02328014
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy acalabrutinib and ACP 319 in B-cell malignancies.
Timeline
- Start
- 2014-12-20
- Primary completion
- 2020-06-01
- Completion
- 2025-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACP-319 | Unknown | 25 mg | Oral |
| Subject | ACP-319 | Unknown | 50 mg | Oral |
| Subject | ACP-319 | Unknown | 100 mg | Oral |
| Subject | Acalabrutinib | Small molecule | 100 mg | Oral |